Published in Arterioscler Thromb Vasc Biol on May 06, 2010
The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov (2012) 3.18
Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol (2010) 0.96
Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res (2011) 0.96
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res (2010) 0.93
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol (2014) 0.91
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res (2014) 0.86
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis (2014) 0.82
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res (2016) 0.79
Beyond genome-wide association studies: the usefulness of mouse genetics in understanding the complex etiology of atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.78
Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. Transl Res (2011) 0.78
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica (Cairo) (2012) 0.76
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract (2017) 0.75
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature (2011) 1.98
The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat Immunol (2012) 1.97
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol (2005) 1.91
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Smc5-Smc6 mediate DNA double-strand-break repair by promoting sister-chromatid recombination. Nat Cell Biol (2006) 1.71
Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2010) 1.68
Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet (2005) 1.62
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther (2005) 1.38
Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. Cell Metab (2013) 1.32
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood (2010) 1.25
Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J (2011) 1.22
Direct mobilisation of lysosomal Ca2+ triggers complex Ca2+ signals. J Cell Sci (2012) 1.21
Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells (2006) 1.18
The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther (2007) 1.16
Sorting motifs in the intracellular domain of the low density lipoprotein receptor interact with a novel domain of sorting nexin-17. J Biol Chem (2004) 1.16
Hrs- and CD63-dependent competing mechanisms make different sized endosomal intraluminal vesicles. Traffic (2014) 1.11
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol (2007) 1.09
Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development. Glia (2010) 1.06
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis (2008) 1.04
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis (2007) 1.03
The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse. Endocrinology (2008) 1.03
Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol (2008) 1.02
Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice. FASEB J (2014) 1.02
The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med (2013) 1.00
Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther (2011) 1.00
Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J Clin Invest (2002) 0.99
Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle (2009) 0.98
Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol (2004) 0.97
β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem (2013) 0.97
Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther (2009) 0.95
Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration. Hum Gene Ther (2008) 0.94
Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc Trans (2010) 0.93
Adaptor protein disabled-2 modulates low density lipoprotein receptor synthesis in fibroblasts from patients with autosomal recessive hypercholesterolaemia. Hum Mol Genet (2007) 0.91
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med (2010) 0.91
Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med (2007) 0.91
Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med (Berl) (2011) 0.91
Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis (2006) 0.91
AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood (2011) 0.89
Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther (2009) 0.87
Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. J Inherit Metab Dis (2012) 0.86
Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther (2013) 0.86
Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis (2004) 0.85
A new pepsin assay to detect pulmonary aspiration of gastric contents among newly intubated patients. Am J Emerg Med (2004) 0.84
Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector. Mol Ther (2010) 0.84
Perinatal gene transfer to the liver. Curr Pharm Des (2011) 0.84
The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis. Mol Ther (2012) 0.82
Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet (2014) 0.82
The case for intrauterine gene therapy. Best Pract Res Clin Obstet Gynaecol (2012) 0.81
Fetal gene therapy: recent advances and current challenges. Expert Opin Biol Ther (2011) 0.80
The concept of prenatal gene therapy. Methods Mol Biol (2012) 0.80
The transmembrane domain and PXXP motifs of ApoE receptor 2 exclude it from carrying out clathrin-mediated endocytosis. J Biol Chem (2003) 0.80
In utero gene transfer to the mouse nervous system. Biochem Soc Trans (2010) 0.79
FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol (2011) 0.79
Animal models for prenatal gene therapy: rodent models for prenatal gene therapy. Methods Mol Biol (2012) 0.79
Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiency. Biochim Biophys Acta (2004) 0.79
Genetic diagnosis of familial hypercholesterolaemia: a mutation and a rare non-pathogenic amino acid variant in the same family. Atherosclerosis (2004) 0.78
Monitoring for potential adverse effects of prenatal gene therapy: use of large animal models with relevance to human application. Methods Mol Biol (2012) 0.78
Premature senescence in cells from patients with autosomal recessive hypercholesterolemia (ARH): evidence for a role for ARH in mitosis. Arterioscler Thromb Vasc Biol (2011) 0.77
The differentiation and engraftment potential of mouse hematopoietic stem cells is maintained after bio-electrospray. Analyst (2009) 0.77
Perinatal gene delivery to the CNS. Ther Deliv (2011) 0.76
Candidate diseases for prenatal gene therapy. Methods Mol Biol (2012) 0.76
Absolutely Exponential Stability and Temperature Control for Gas Chromatograph System Under Dwell Time Switching Techniques. IEEE Trans Cybern (2015) 0.75
A single point mutation in the low-density lipoprotein receptor switches the degradation of its mature protein from the proteasome to the lysosome. Int J Biochem Cell Biol (2006) 0.75
Sampled-Data-Based Consensus and $L_{2}$ -Gain Analysis for Heterogeneous Multiagent Systems. IEEE Trans Cybern (2016) 0.75
Targeting the respiratory muscles of fetal sheep for prenatal gene therapy for Duchenne muscular dystrophy. Am J Obstet Gynecol (2005) 0.75
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep (2017) 0.75
Observer-Based Adaptive NN Control for a Class of Uncertain Nonlinear Systems With Nonsymmetric Input Saturation. IEEE Trans Neural Netw Learn Syst (2016) 0.75
Input-to-state stability of switched nonlinear systems with time delays under asynchronous switching. IEEE Trans Cybern (2013) 0.75
Monitoring for potential adverse effects of prenatal gene therapy: mouse models for developmental aberrations and inadvertent germ line transmission. Methods Mol Biol (2012) 0.75
Redesigned Predictive Event-Triggered Controller for Networked Control System With Delays. IEEE Trans Cybern (2016) 0.75
Vector systems for prenatal gene therapy: choosing vectors for different applications. Methods Mol Biol (2012) 0.75
Choice of surrogate and physiological markers for prenatal gene therapy. Methods Mol Biol (2012) 0.75